news aktuell GmbH

Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories

Share
  • Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment
  • Agreement includes further product development activities for Clinigen Limited
  • Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally

(Munich / London / Athens) Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limitedto acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers. 

Lamda has not only acted as Clinigen’s sole development center but has also established a well-earned reputation as a highly reliable contract development organization (CDO) for third party customers. Under a pharmaceutical development services agreement, Lamda will continue to provide services for Clinigen Limited. 

The Athens site, a mere 15 minute drive from the airport, is fully equipped with state of the art equipment including the handling of potent drugs, established Quality systems and a proven track record of delivering complex developments on time for customers. 

A highly experienced management team and well-trained staff will continue to focus on complex product development for growing markets in Europe, Japan, and North America. Lamda will offer an expanded range of pharmaceutical development, regulatory affairs and supply chain management services for a wide range of dosage forms including complex and high potent oral solids, differentiated oral liquids, injectables and topical medicines. As part of the transaction, Adragos secures royalty streams for products stemming from previous co-developments. 

David Bryant, Interim CEO of Clinigen Limited states: "We are pleased to have found in Adragos Pharma a trusted partner to build on the success story of Lamda with its great team taking it to the next level while also continuing to support Clinigen as we focus on providing high-value services to the biopharma industry.”

Dr. Andreas Raabe, CEO of Adragos Pharma commended the “impressive track record and professional service mindset at Lamda”. He noted that “Lamda combines differentiated product development capabilities with substantial scale, an essential combination for our international group.” 

The exact terms of the transaction will not be disclosed. Completion of the transaction is subject to customary conditions precedent.

About Adragos
Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office. Adragos Pharma currently operates four production sites in France, Germany, and Japan.www.adragos-pharma.com 

About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries, and provides access in more than 120 countries every year. For more information on Clinigen, please visit: www.clinigengroup.com

Contacts

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase9.5.2025 12:00:00 CEST | Press release

(Vienna, Austria) Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease. Biomay is the FDA-approved manufacturer of recombinant Cas9 as the essential component of CASGEVY®, the very first CRISPR genome editing product on the market. Biomay’s Cas9 (internal code “BMC9”) is based on the classical wild-type Cas9 nuclease from Streptococcus pyogenes. The Cas9 manufacturing process has been de novo developed, GMP-implemented and PPQ-validated by Biomay. GMP and RUO manufacturing is performed by fermentation with E. coli and by purification with chromatographic methods. By quality control with a comprehensive set of validated analytical assays, the consistent

mAInthink GmbH: Technological Breakthrough: Hallucination-Free Superintelligence Achieves 99.99% Strategic Accuracy – Germany Gains Permanent Strategic Superiority9.5.2025 10:57:00 CEST | Press release

Worms, May 9, 2025 – The mAInthink GmbH has achieved a technological breakthrough that redefines the future of strategic decision-making: With the development of StratePlan, a hallucination-free superintelligence delivering verified 99.99% strategic accuracy, Germany secures permanent technological, economic, and geopolitical superiority – operationally deployable and scientifically validated.

HEIDELBERG/Amperfied presents new DC fast charging solution with comprehensive range of services: Focus on dynamic power distribution and high availability7.5.2025 08:56:00 CEST | Press release

Offer is aimed at the increasing demand from charging parks, logistics depots and haulage fleets Amperfied addresses demand for fast charging system solutions with new DC product and performance-based offering DC becomes part of an availability-based operating hours model Modular technology for optimum utilization of the charging system and small footprint Debut at the Power2Drive 2025 Amperfied GmbH, a subsidiary of Heidelberger Druckmaschinen AG (HEIDELBERG), is entering the market for fast charging solutions complete with a comprehensive range of services. At the Power2Drive trade fair in Munich, the company will unveil its modular DC fast charging solution called Amperfied Dynamic DC, which focuses on availability and efficiency. The offering is aimed primarily at the growing demand from charging parks, logistics depots and haulage fleets for high-availability system solutions. This is because only with fast and functional charge points can charging infrastructure operators (CPOs)

HEIDELBERG holds its ground in a difficult market environment in FY 2024/25 - targets achieved, significant increase in incoming orders compared to previous year6.5.2025 08:52:59 CEST | Press release

Sales and adjusted EBITDA margin at previous year's level according to preliminary figures Free cash flow excluding special items clearly positive at around € 50 million Rising order intake compared to previous year lays the foundation for a good start to FY 2025/26 Additional, positive order impetus expected from China Print trade fair in May Adjusted EBITDA margin to rise to around 8 percent in FY 2025/26

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye